Cargando…

Plant-Based Oral Vaccines: Results of Human Trials

Vaccines consisting of transgenic plant-derived antigens offer a new strategy for development of safe, inexpensive vaccines. The vaccine antigens can be eaten with the edible part of the plant or purified from plant material. In phase 1 clinical studies of prototype potato- and corn-based vaccines,...

Descripción completa

Detalles Bibliográficos
Autor principal: Tacket, C. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121496/
https://www.ncbi.nlm.nih.gov/pubmed/19401823
http://dx.doi.org/10.1007/978-3-540-70868-1_6
_version_ 1783515215388737536
author Tacket, C. O.
author_facet Tacket, C. O.
author_sort Tacket, C. O.
collection PubMed
description Vaccines consisting of transgenic plant-derived antigens offer a new strategy for development of safe, inexpensive vaccines. The vaccine antigens can be eaten with the edible part of the plant or purified from plant material. In phase 1 clinical studies of prototype potato- and corn-based vaccines, these vaccines have been safe and immunogenic without the need for a buffer or vehicle other than the plant cell. Transgenic plant technology is attractive for vaccine development because these vaccines are needle-less, stable, and easy to administer. This chapter examines some early human studies of oral transgenic plant-derived vaccines against enterotoxigenic Escherichia coli infection, norovirus, and hepatitis B.
format Online
Article
Text
id pubmed-7121496
institution National Center for Biotechnology Information
language English
publishDate 2009
record_format MEDLINE/PubMed
spelling pubmed-71214962020-04-06 Plant-Based Oral Vaccines: Results of Human Trials Tacket, C. O. Plant-produced Microbial Vaccines Article Vaccines consisting of transgenic plant-derived antigens offer a new strategy for development of safe, inexpensive vaccines. The vaccine antigens can be eaten with the edible part of the plant or purified from plant material. In phase 1 clinical studies of prototype potato- and corn-based vaccines, these vaccines have been safe and immunogenic without the need for a buffer or vehicle other than the plant cell. Transgenic plant technology is attractive for vaccine development because these vaccines are needle-less, stable, and easy to administer. This chapter examines some early human studies of oral transgenic plant-derived vaccines against enterotoxigenic Escherichia coli infection, norovirus, and hepatitis B. 2009 /pmc/articles/PMC7121496/ /pubmed/19401823 http://dx.doi.org/10.1007/978-3-540-70868-1_6 Text en © Springer-Verlag Berlin Heidelberg 2009 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Tacket, C. O.
Plant-Based Oral Vaccines: Results of Human Trials
title Plant-Based Oral Vaccines: Results of Human Trials
title_full Plant-Based Oral Vaccines: Results of Human Trials
title_fullStr Plant-Based Oral Vaccines: Results of Human Trials
title_full_unstemmed Plant-Based Oral Vaccines: Results of Human Trials
title_short Plant-Based Oral Vaccines: Results of Human Trials
title_sort plant-based oral vaccines: results of human trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121496/
https://www.ncbi.nlm.nih.gov/pubmed/19401823
http://dx.doi.org/10.1007/978-3-540-70868-1_6
work_keys_str_mv AT tacketco plantbasedoralvaccinesresultsofhumantrials